News Column

Marina Biotech Receives Patent for Smarticles

June 11, 2014

Marina Biotech reported that a decision to grant a patent has been issued for the Company's Smarticles delivery technology in Japan.

According to a release from the company, the claims of this National Stage Application cover delivery technology based on Marina's proprietary Smarticles amphoteric liposomes and directly support the clinical programs of the company's licensees ProNAi Therapeutics and Mirna Therapeutics. The granted claims cover amphoteric liposomes that are suitable for tailoring delivery systems for the release of therapeutic cargos, including DNA oligonucleotides, antisense and/or decoy entities, ribozymes, DNAzymes or aptamers, as well as proteins, peptides, and RNA-based drugs such as siRNA and miRNA.

"The decision to grant from the Japan Patent Office further extends the scope of our intellectual property covering our Smarticles technology, while the positive clinical delivery experiences of both ProNAi and Mirna provide significant scientific and clinical validation of Smarticles," stated J. Michael French, President and CEO of Marina Biotech. "We believe that SMARTICLES, which is broadly covered by the company's patent estate, is a leading means for the successful delivery of nucleic acid compounds. Further, we believe it is the only delivery technology in development that has delivered both a single- and a double-stranded oligonucleotide in a clinical setting. We believe that the breadth and flexibility of the Smarticles platform provides significant competitive advantages and differentiation as we move forward with our rare disease clinical pipeline."

Marina Biotech is an oligonucleotide therapeutics company.

More information and complete details:

www.marinabio.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Beauty Close - Up